secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hims & Hers Health, Inc. (HIMS)
CIK:        0001773751
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001773751-25-000352
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hims & Hers Q3 revenue $599M (+49% YoY), Adj. EBITDA $78.4M; narrows FY25 guidance
--------------------------------------------------------------------------------

- Q3 revenue $599M (+49% YoY), net income $15.8M (prior-year $75.6M included $60.8M tax benefit)
- Adj. EBITDA $78.4M (+53% YoY); subscribers 2.47M (+21% YoY); monthly online revenue per subscriber $80 (+19% YoY)
- Gross margin 74% vs 79% YoY, hit by shorter shipping cadences for weight-loss offerings
- FY25 revenue guidance narrowed to $2.34-2.36B, Adj. EBITDA guidance $307-317M
- Entering testosterone, menopause care; discussions with Novo Nordisk for Wegovy; GRAIL investment

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1773751/000177375125000352/0001773751-25-000352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1773751/000177375125000352/hims-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001773751-25-000352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer